JonesResearch downgraded Korro Bio (KRRO) to Hold from Buy without a price target after the company announced KRRO-110 did not reach target levels of functional alpha-1 antitrypsin. The firm cites the stock’s lack of near-term catalysts and failure to demonstrate proof-of-concept for its RNA editing platform for the downgrade.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO: